Page results
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
A national study with initial results shows steroid dexamethasone may substantially reduce mortality in severely ill Covid-19 patients.
-
This easy read page offers advice for patients on managing pain after an operation.
-
This series of wellbeing videos have been designed to help people manage the side effects of cancer treatment.
-
The Clinical and Research Informatics Unit at UCLH consists of a team of clinicians, researchers, software developers, business intelligence analysts and data scientists working together to develop a robust environment for the analysis of clinical data.
-
This page explains what sperm banking is, how it works and how it can benefit you.
-
A UCLH rheumatology team is leading an exciting project to help understand the reasons for young people missing their hospital appointments and find ways to improve this.
-
The Integrated Children and Adolescent Service is a long-established outpatient service of the Royal London Hospital for Integrated Medicine at UCLH.
-
A new surgical technique could remove the risk of urinary incontinence after surgery to remove the prostate for men with prostate cancer.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology